IKZF1 and acute lymphoblastic leukemia: In the Ph/−/ B-ALL subgroup, IKZF1 deletions continued to demonstrate statistically significant effect on the EFS (median 16 months versus 8 months, p = 0.005) and OS (median 24 months versus 8 months for patients with deletions, p = 0.044).